Vilija Oke
7PUBLICATIONS
18CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Apr 09, 2026
Lectin pathway of complement in SLE: MAP-1 as a marker of haematological manifestations and elevated type I interferon activity.Linnea Lindelöf, Peter Garred, Mun-Gwan Hong
|Jan 23, 2026
Guselkumab Improves Patient-Reported Outcomes Among Participants with Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors in the COSMOS Study.Laure Gossec, Xenofon Baraliakos, James Galloway
|Sep 14, 2022
Interleukin (IL) 16: a candidate urinary biomarker for proliferative lupus nephritis.Aliisa Häyry, Francesca Faustini, Agneta Zickert
|Oct 18, 2021
Four Systemic Lupus Erythematosus Subgroups, Defined by Autoantibodies Status, Differ Regarding HLA-DRB1 Genotype Associations and Immunological and Clinical Manifestations.Lina-Marcela Diaz-Gallo, Vilija Oke, Emeli Lundström
|May 01, 2021
Proteome study of cutaneous lupus erythematosus (CLE) and dermatomyositis skin lesions reveals IL-16 is differentially upregulated in CLE.Timothy B Niewold, Alexander Meves, Julia S Lehman
|May 01, 2019
High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus.Vilija Oke, Iva Gunnarsson, Jessica Dorschner
Pageof 2
Frequent Collaborators
3 joint publications
Elisabet Svenungsson
2 joint publications
Lina-Marcela Diaz-Gallo
2 joint publications
Timothy B Niewold
1 joint publications
Daniel J Birmingham
1 joint publications
Leonid Padyukov
1 joint publications
Francesca Faustini
1 joint publications
Laure Gossec
1 joint publications
Xenofon Baraliakos
1 joint publications
James Galloway
1 joint publications
Petros Sfikakis
